Schizophrenia-spectrum disorder (F20.x und F25.x), ARMS, healthy controls
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Capacity for informed consent
Exclusion criteria
Exclusion criteria: Exclusion criteria for healthy controls - Current or past neurological disorder (e.g., migraine or epilepsy), including traumatic brain injury - Current or past severe somatic illness with a potential impact on cognitive performance, including oncological and autoimmune diseases - Current or past ophthalmological disorder, including color blindness, red–green color vision deficiency, strabismus, and pronounced astigmatism - Current or past audiological disorder, including hearing loss, deafness, and tinnitus - Presence of a mental disorder - Family history of neuropsychiatric disorders - Use of medication - Regular use of hallucinogenic drugs and alcohol within the past 3 months Exclusion criteria for patients - Current or past neurological disorder (e.g., migraine or epilepsy), including traumatic brain injury - Current or past severe somatic illness, including oncological and autoimmune diseases - Current or past ophthalmological disorder, including color blindness and red–green color vision deficiency - Current or past audiological disorder, including hearing loss, deafness, and tinnitus - Regular use of hallucinogenic drugs and alcohol within the past 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Correlation between the severity and frequency of basic symptoms and positive symptoms - Correlation between the severity and frequency of basic symptoms and negative symptoms - Correlation between the severity and frequency of basic symptoms and cognitive impairments - Correlation between the severity and frequency of basic symptoms and participants’ level of functioning | — |
Secondary
| Measure | Time frame |
|---|---|
| - Correlation between the severity and frequency of basic symptoms and participants’ level of functioning - Correlation between the severity and frequency of basic symptoms and PRS-Resilience and PRS-Risk, respectively | — |
Countries
Germany
Contacts
Klinik für Psychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Frankfurt, Goethe Universität